The Prague Post - Tests of HIV vaccine using mRNA technology have begun

EUR -
AED 4.133016
AFN 79.014964
ALL 98.31862
AMD 437.773181
ANG 2.028041
AOA 1029.611125
ARS 1251.855289
AUD 1.757365
AWG 2.028278
AZN 1.917126
BAM 1.956188
BBD 2.27115
BDT 136.667097
BGN 1.957015
BHD 0.424126
BIF 3346.233724
BMD 1.125258
BND 1.460277
BOB 7.772472
BRL 6.358049
BSD 1.124823
BTN 95.99718
BWP 15.25155
BYN 3.680997
BYR 22055.058879
BZD 2.259428
CAD 1.566056
CDF 3235.116973
CHF 0.935354
CLF 0.027388
CLP 1050.991307
CNY 8.130384
CNH 8.147347
COP 4784.788761
CRC 570.908121
CUC 1.125258
CUP 29.81934
CVE 110.286867
CZK 24.935346
DJF 200.293482
DKK 7.46036
DOP 66.183122
DZD 149.756373
EGP 56.958762
ERN 16.878872
ETB 150.919382
FJD 2.555122
FKP 0.847092
GBP 0.847505
GEL 3.100118
GGP 0.847092
GHS 14.790472
GIP 0.847092
GMD 80.45191
GNF 9740.931344
GTQ 8.651715
GYD 236.009453
HKD 8.752319
HNL 29.224002
HRK 7.533489
HTG 146.89782
HUF 404.826792
IDR 18607.661882
ILS 3.992618
IMP 0.847092
INR 96.074256
IQD 1473.603486
IRR 47387.433667
ISK 146.914045
JEP 0.847092
JMD 178.79545
JOD 0.79826
JPY 163.330066
KES 145.386217
KGS 98.404068
KHR 4502.852769
KMF 487.764367
KPW 1012.925798
KRW 1575.676432
KWD 0.345139
KYD 0.937357
KZT 580.499938
LAK 24314.604801
LBP 100782.086532
LKR 336.073647
LRD 224.962604
LSL 20.458156
LTL 3.322595
LVL 0.680658
LYD 6.164222
MAD 10.405863
MDL 19.278223
MGA 5060.958465
MKD 61.534193
MMK 2362.75524
MNT 4023.127953
MOP 9.011706
MRU 44.812885
MUR 51.435748
MVR 17.340245
MWK 1950.369369
MXN 21.946483
MYR 4.835229
MZN 71.903861
NAD 20.459702
NGN 1811.046958
NIO 41.391333
NOK 11.667205
NPR 153.595088
NZD 1.909774
OMR 0.433205
PAB 1.124813
PEN 4.086719
PGK 4.66876
PHP 62.416374
PKR 316.774807
PLN 4.23953
PYG 8992.783008
QAR 4.104414
RON 5.118577
RSD 117.233244
RUB 93.958644
RWF 1616.870287
SAR 4.220687
SBD 9.39686
SCR 15.963385
SDG 675.715336
SEK 10.919375
SGD 1.46018
SHP 0.884276
SLE 25.576714
SLL 23596.081583
SOS 642.82174
SRD 40.798425
STD 23290.570909
SVC 9.841951
SYP 14633.498546
SZL 20.448873
THB 37.125708
TJS 11.641705
TMT 3.949656
TND 3.385971
TOP 2.635468
TRY 43.601462
TTD 7.641447
TWD 34.013207
TZS 3035.387599
UAH 46.726103
UGX 4116.816245
USD 1.125258
UYU 47.019323
UZS 14487.872525
VES 102.509005
VND 29232.517709
VUV 135.84037
WST 3.117633
XAF 656.081251
XAG 0.034527
XAU 0.000337
XCD 3.041067
XDR 0.808666
XOF 656.087083
XPF 119.331742
YER 275.127045
ZAR 20.483867
ZMK 10128.668579
ZMW 29.610608
ZWL 362.332651
  • RBGPF

    2.8600

    65.86

    +4.34%

  • CMSD

    0.0200

    22.35

    +0.09%

  • BCC

    -0.0700

    89.51

    -0.08%

  • CMSC

    -0.0100

    22.1

    -0.05%

  • JRI

    -0.0020

    12.948

    -0.02%

  • BCE

    0.6550

    22.885

    +2.86%

  • SCS

    -0.0400

    10.44

    -0.38%

  • NGG

    0.3900

    70.57

    +0.55%

  • RIO

    0.6600

    59.84

    +1.1%

  • AZN

    0.6400

    67.94

    +0.94%

  • GSK

    -0.0450

    36.825

    -0.12%

  • RYCEF

    -0.1400

    10.46

    -1.34%

  • RELX

    0.2286

    53.73

    +0.43%

  • VOD

    0.0750

    9.325

    +0.8%

  • BP

    1.1450

    29.735

    +3.85%

  • BTI

    -1.6500

    41.65

    -3.96%

Tests of HIV vaccine using mRNA technology have begun
Tests of HIV vaccine using mRNA technology have begun

Tests of HIV vaccine using mRNA technology have begun

Testing in humans of an HIV vaccine that uses messenger RNA technology has begun, the biotech firm Moderna and the International AIDS Vaccine Initiative said Thursday.

Text size:

This Phase 1 trial is being carried out in the United States among 56 healthy adults who are HIV negative.

Despite four decades of research, doctors have yet to develop a vaccine to protect people from the virus that causes AIDS, which kills hundreds of thousands of people around the world each year.

But hopes have been stirred with the success of mRNA technology, which allowed for the development of Covid-19 vaccines in record time, including one from Moderna.

The goal of the vaccine now being tested is to stimulate production of a kind of antibody called "broadly neutralizing antibodies," or bnAbs, which can act against the many variants of HIV that are circulating today.

The vaccine is supposed to teach B lymphocytes, which are part of the immune system, to generate these antibodies.

In this trial, participants are injected with an immunogen -- a substance that can trigger an immune response -- and then a booster immunogen later.

These substances will be delivered with mRNA technology.

"The induction of bnAbs is widely considered to be a goal of HIV vaccination, and this is the first step in that process," Moderna and the IAVI, a research organization, said in a statement.

"Further immunogens will be needed to guide the immune system on this path, but this prime-boost combination could be the first key element of an eventual HIV immunization regimen," said David Diemert, a lead investigator at one of the four sites where the trial is being carried out, George Washington University in the US capital.

The immunogens used in this trial were developed by IAVI and the Scripps Research Institute, with support from the Bill & Melinda Gates Foundation, the US National Institute of Allergy and Infectious Diseases and Moderna.

A first trial last year tested the first immunogen but without employing mRNA technology. It showed that the desired immune response was triggered in dozens of people taking part in the research.

The next step was to bring in Moderna with its new mRNA technique.

"Given the speed with which mRNA vaccines can be produced, this platform offers a more nimble and responsive approach to vaccine design and testing," the Moderna-IAVI statement said.

"The search for an HIV vaccine has been long and challenging, and having new tools in terms of immunogens and platforms could be the key to making rapid progress toward an urgently needed, effective HIV vaccine," said Mark Feinberg, the CEO of IAVI.

Q.Pilar--TPP